Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Omaveloxolone |
Synonyms | |
Therapy Description |
Omaveloxolone (RTA 408) is an activator of Nrf2 (NFE2L2) and inhibitor of NF-kappa B, which inhibits tumor growth through regulation of antioxidant and pro-inflammatory gene expression (PMID: 25897966, PMID: 31487581). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Omaveloxolone | RTA 408|RTA-408 | Omaveloxolone (RTA 408) is an activator of Nrf2 (NFE2L2) and inhibitor of NF-kappa B, which inhibits tumor growth through regulation of antioxidant and pro-inflammatory gene expression (PMID: 25897966, PMID: 31487581). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02259231 | Phase Ib/II | Ipilimumab Nivolumab Omaveloxolone | RTA 408 Capsules in Patients With Melanoma - REVEAL | Completed | USA | 0 |